Start your own journey to clinic

Please provide us with a few details so that we can match you with the right expert in your field.


Thank you, your request has been received.

We're busy connecting you with an expert, who will be in touch as soon as possible.

Oops! Something went wrong while submitting the form. Please try again or email us at


Immuno-oncology has become a crucial pillar of therapy against cancer. Antibody-based biologics that target immune checkpoint inhibitors were the first-generation cancer immunotherapy developed and show remarkable efficacy in patients with advanced cancer. Unfortunately, not all patients benefit from these therapies due to various resistance mechanisms in tumours, leading to diminished efficacy and ultimately to tumour persistence or rebound. Despite these challenges, the field of immunotherapy continues to grow and its focus now includes various therapeutic approaches modulating one or more human immune cell types.

Connected servicesMore informationSpeak to an expert

Connected expertise and services

Connected expertise and services

A more in-depth view

The tumour microenvironment is intricately complex, conditioning stromal cells to support cancer cell viability, proliferation, and resistance to anti-cancer immunotherapies. Understanding the molecular underpinnings of these processes is crucial for identifying promising targets for pharmacological inhibition. We offer in vitro assays that faithfully recapitulate cancer pathology, aiding in holistic research. 

Our disease modelling capabilities for immuno-oncology are:


·     M2-like macrophage differentiation assay

·     M2-like reprogramming assay

·     M2-like mediated T cell suppression assay

·     M2-like mediated EMT assay

·     M2-like phagocytosis and efferocytosis assay


Dendritic cell (DC):

·     DC activation assay

·     DC-Tcell coculture assay (MLR, autologous assay using peptide pools)

Myeloid derived suppressor cells (MDSC):

·     MDSC-mediatedT cell suppression

T lymphocyte:

·     Tcell activation assays (PBMC and CD3+)

·     DC-Tcell coculture assay (MLR, autologous assay using peptide pools)

·     Tcell-mediated tumour cell killing assay

·     ExhaustedT cell assay

·     Tcell chemotaxis assay

·     iTreg differentiation assay

·     iTreg and nTreg suppression assay

NK cell:

·     NKcell activation assay

·     NKcell natural cytotoxicity assay

·     Antibody mediated cellular cytotoxicity assay (ADCC)


·     Cancer-associated fibroblast (CAF) activation assay


·     Cancercell growth and apoptosis assay using 2D and 3D spheroid model

·     Cancercell migration assay (EMT assay)

·     Immunogeniccell death assay

Connected resources